Study Graphic

You may be eligible if:

  • You are a healthy male or female 18-55 years of age
  • You are able to meet all eligibility criteria
  • You are able to comply with all study visits

Study number: C1171007

Be compensated for your time: $2650.00 for completion of the study

 The Pfizer New Haven Clinical Research Unit is conducting a study of a new investigational drug to treat people with Nonalcoholic Steatohepatitis (NASH). NASH is inflammation of the liver and liver damage caused by buildup of fat in the liver (“fatty liver disease”).

You will be in this study up to about 39 days. This does not include the time between screening and dosing, which can be up to 28 days.

 This study involves:

  • 2 dosing periods (during 1 continuous admission)
  • 9 overnight stays
  • 1 follow-up phone call (about 28 to 32 days after the last dose of study drug) 
  • There will be at least 5 days between each dose.

Please review more information about the study: C1171007 Guidelines Restrictions Dates v14Feb2019